Pilot study of gemtuzumab ozogamicin (GO), fludarabine, cytarabine and idarubicin combined regimen (GO-FLAI) as first-line induction therapy plus GO alone as consolidation therapy for elderly acute myeloid leukemia patients

Acta Haematol. 2007;118(1):7-9. doi: 10.1159/000100992. Epub 2007 Mar 26.

Authors

Maria Teresa Pirrotta¹, Monica Bocchia, Alessandro Bucalossi, Marzia Defina, Francesco Forconi, Alessandro Gozzetti, Francesco Lauria

Affiliation

¹ Department of Hematology, University of Siena, Siena, Italy. [email protected]

PMID: 17389781
DOI: 10.1159/000100992

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Age Factors
Aged
Aminoglycosides / administration & dosage
Antibodies, Monoclonal / administration & dosage
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
Disease-Free Survival
Dose-Response Relationship, Drug
Drug Administration Schedule
Feasibility Studies
Female
Gemtuzumab
Humans
Idarubicin / administration & dosage
Leukemia, Myeloid, Acute / diagnosis
Leukemia, Myeloid, Acute / drug therapy*
Leukemia, Myeloid, Acute / mortality*
Male
Middle Aged
Pilot Projects
Prognosis
Remission Induction
Risk Factors
Severity of Illness Index
Survival Rate
Treatment Outcome
Vidarabine / administration & dosage
Vidarabine / analogs & derivatives

Substances

Aminoglycosides
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Gemtuzumab
Vidarabine
fludarabine
Idarubicin